Van Andel Institute scientists have developed an improved technique to comprehensively profile DNA methylation in single cells, an advance that will help researchers better study the role of epigenetics in cancer and other diseases.
Researchers develop nicotinamide N-methyl transferase inhibitor to block ovarian cancer tumor growth
A team led by researchers at the University of Chicago discovered how to block nicotinamide N-methyl transferase, an enzyme that is involved in the progression of high-grade serous ovarian cancer.
A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.
Researchers at UT Southwestern Medical Center have discovered how a hormone interacts with a receptor on the surface of immune cells to shield cancer cells from the body’s natural defenses.
NCI has initiated a pilot study to address the feasibility of using multi-cancer detection, or MCD, tests in future randomized controlled trials.
The Ohio State University Comprehensive Cancer has launched a first-of-its-kind clinical trial.
Stereotactic brain-directed radiation showed positive outcomes that support the use of targeted radiation in the future, according to a study led by investigators from Mass General Brigham published in the Journal of Clinical Oncology.
A treatment approach using the drug cyclophosphamide can prevent most graft-versus-host disease in blood cancer patients without a donor match, new UVA Cancer Center research reveals.
Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage 3 melanoma remained alive, according to new results from a study led by researchers at the University of Texas MD Anderson Cancer Center.
The aging process known as senescence is a mechanism involved in the failure of CAR T-cell therapy, according to a study by researchers at the Mayo Clinic.
